[301 Pages Report] The global epiglottitis treatment demand is presently valued at around US$ 10 Billion and is forecasted to develop at a CAGR of 4.8% to reach US$ 16 Billion by 2032. As of 2021, the market was valued at US$ 9.7 Billion, and is slated to register a Y-o-Y growth rate of 3.1% by 2022.
There is a huge spike in the prevalence of the disease is likely to significantly contribute to the epiglottitis treatment market. The spike in the diagnosis of the abovementioned condition as well as developing medical infrastructure is anticipated to surge the demand for epiglottitis treatment in this region during the forecast period.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | US$ 9.7 Billion |
| Expected Market Value (2022) | US$ 10 Billion |
| Anticipated Forecast Value (2032) | US$ 16 Billion |
| Projected Growth Rate (2022 to 2032) | 4.8% CAGR |
Epiglottitis is a bacterial viral infection that causes inflammation and swelling of the epiglottis. The epiglottis is a cartilage structure located at the back of the throat, beneath the tongue, and its function is to close over the trachea when foods are swallowed. Epiglottitis causes breathing problems, tachycardia, swelling of supraglottic tissue, inspiratory stridor, pharyngitis, cervical lymph nodes, and inability to deal with secretion.
Drooling, dysphagia, dysphonia, and distressed inspiration efforts are all symptoms of epiglottitis. Adult epiglottitis differential diagnosis includes Infectious process and non-infectious disease, infectious process symptoms include diphtheria, pertussis, croup, tracheobronchitis, peripharyngeal, and others, and non-infectious disease symptoms include allergic reaction, angioneurotic, oedema, reflex laryngospasm, systemic lupus, and others.
Epiglottitis can affect people of any age; however, it is usually diagnosed in males rather than females and occurs in children aged 2 to 8 years. Epiglottitis is primarily caused by Haemophilus influenzae type B (HIB), but other bacteria and viruses such as Streptococcus pneumonia, Streptococcus A, B, and C, and Staphylococcus aureus can also cause epiglottitis inflammation.
A blood test to identify bacteria, an x-ray, and a CT scan to determine the level of swelling are used to diagnose epiglottitis. Epiglottitis is treated with an oxygen mask, which delivers oxygen to the lungs, and a tracheostomy, which may be required to bypass the swelling in the throat.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
During the forecast period, the increasing prevalence and incidence rate of epiglottitis are expected to contribute to the growth of the Epiglottitis Treatment market. HIB vaccination and third generation cephalosporin, which is administered via the parental route (intramuscular/intravenous) and is effective against Haemophilus influenzae type B, which causes Epiglottitis disease, is expected to drive the Epiglottitis Treatment market.
Because epiglottitis is an inflammatory disease caused by a variety of organisms, antibiotics and the combination of an intravenous ant staphylococcal agent are expected to grow significantly during the Epiglottitis Treatment market forecast period. Furthermore, the soaring unhealthy lifestyle combined with lack of cleanliness is anticipated to boost the market’s growth.
Even though epiglottitis treatment is flourishing, there are still some factors impeding the growth of the worldwide epiglottitis treatment market. Epiglottitis Treatment drugs can occasionally cause depression and other side effects, limiting the Epiglottitis Treatment market's growth. The primary restraint of the Epiglottitis Treatment market is a lack of access to healthcare facilities, affordability constraints, and a lack of market penetration of approved drugs.
Principal Consultant
The Epiglottitis Treatment market in Asia Pacific is projected to thrive at a substantial CAGR of 4.5% over the assessment period from 2022 to 2032. The inclusion of one of the largest economies, such as India and China, is projected to boost the market of the APAC epiglottitis treatment market. As a result of the availability of funds for research and development, this region is expected to observe significant growth in the epiglottitis treatment market.
On the other hand, APAC is further experiencing prominent growth prospects in the epiglottitis treatment market due to increased bacterial infection prevalence as well as increased investment in healthcare infrastructure.
According to Future Market Insights, North America is predicted to dominate the worldwide Epiglottitis Treatment market with a significant CAGR of 4.9%, due to higher adoption and number of customers using Epiglottitis Treatment, as well as increased awareness about Epiglottitis disease. Around 7 million Americans have weak immune system which is also one of the causes of epiglottitis.
In addition to that, an estimated 1.5 million people over the age of 12 use cocaine each month In the United States which is another cause of epiglottitis. Moreover, due to the recent technological advancements and the presence of a variety of novel drug molecules to improve the treatment procedure in the region, the North America epiglottitis treatment market is anticipated to flourish during the forecast period from 2022 to 2032.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global epiglottitis treatment market is a moderately fragmented market. Abbott, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Roche Holding AG, and others are some of the market participants identified in the global Epiglottitis Treatment market.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5% from 2022 to 2032 |
| Market Value in 2022 | US$ 10 Billion |
| Market Value in 2032 | US$ 16 Billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global epiglottitis treatment market to expand at a 5% value CAGR by 2032
Asia Pacific is expected to be the most opportunistic Epiglottitis Treatment market, expanding at a 4.5% CAGR
Abbott, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd, GlaxoSmithKline plc, Johnson & Johnson and Roche Holding AG, are some prominent Epiglottitis Treatment manufacturers
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Epiglottitis Treatment Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) Analysis By Drug, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug, 2022-2032 5.3.1. Broad-spectrum Antibiotic 5.3.2. Targeted Antibiotic 5.3.3. Steroid Medication 5.4. Y-o-Y Growth Trend Analysis By Drug, 2017-2021 5.5. Absolute $ Opportunity Analysis By Drug, 2022-2032 6. Global Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032 6.3.1. Oral 6.3.2. Parental 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032 7. Global Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032 7.3.1. Hospitals Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Drug Stores 7.3.4. Clinics 7.3.5. Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 7.5. Absolute $ Opportunity Analysis By End User, 2022-2032 8. Global Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.K. 9.2.1.2. Canada 9.2.2. By Drug 9.2.3. By Route of Administration 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug 9.3.3. By Route of Administration 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug 10.2.3. By Route of Administration 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug 10.3.3. By Route of Administration 10.3.4. By End User 10.4. Key Takeaways 11. Europe Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. U.K. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug 11.2.3. By Route of Administration 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug 11.3.3. By Route of Administration 11.3.4. By End User 11.4. Key Takeaways 12. Asia Pacific Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Malaysia 12.2.1.5. Singapore 12.2.1.6. Australia 12.2.1.7. Rest of Asia Pacific 12.2.2. By Drug 12.2.3. By Route of Administration 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug 12.3.3. By Route of Administration 12.3.4. By End User 12.4. Key Takeaways 13. MEA Epiglottitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of MEA 13.2.2. By Drug 13.2.3. By Route of Administration 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug 13.3.3. By Route of Administration 13.3.4. By End User 13.4. Key Takeaways 14. Key Countries Epiglottitis Treatment Market Analysis 14.1. U.K. 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2021 14.1.2.1. By Drug 14.1.2.2. By Route of Administration 14.1.2.3. By End User 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2021 14.2.2.1. By Drug 14.2.2.2. By Route of Administration 14.2.2.3. By End User 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2021 14.3.2.1. By Drug 14.3.2.2. By Route of Administration 14.3.2.3. By End User 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2021 14.4.2.1. By Drug 14.4.2.2. By Route of Administration 14.4.2.3. By End User 14.5. Rest of Latin America 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2021 14.5.2.1. By Drug 14.5.2.2. By Route of Administration 14.5.2.3. By End User 14.6. Germany 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2021 14.6.2.1. By Drug 14.6.2.2. By Route of Administration 14.6.2.3. By End User 14.7. U.K. 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2021 14.7.2.1. By Drug 14.7.2.2. By Route of Administration 14.7.2.3. By End User 14.8. France 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2021 14.8.2.1. By Drug 14.8.2.2. By Route of Administration 14.8.2.3. By End User 14.9. Spain 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2021 14.9.2.1. By Drug 14.9.2.2. By Route of Administration 14.9.2.3. By End User 14.10. Italy 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2021 14.10.2.1. By Drug 14.10.2.2. By Route of Administration 14.10.2.3. By End User 14.11. Rest of Europe 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2021 14.11.2.1. By Drug 14.11.2.2. By Route of Administration 14.11.2.3. By End User 14.12. China 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2021 14.12.2.1. By Drug 14.12.2.2. By Route of Administration 14.12.2.3. By End User 14.13. Japan 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2021 14.13.2.1. By Drug 14.13.2.2. By Route of Administration 14.13.2.3. By End User 14.14. South Korea 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2021 14.14.2.1. By Drug 14.14.2.2. By Route of Administration 14.14.2.3. By End User 14.15. Malaysia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2021 14.15.2.1. By Drug 14.15.2.2. By Route of Administration 14.15.2.3. By End User 14.16. Singapore 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2021 14.16.2.1. By Drug 14.16.2.2. By Route of Administration 14.16.2.3. By End User 14.17. Australia 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2021 14.17.2.1. By Drug 14.17.2.2. By Route of Administration 14.17.2.3. By End User 14.18. Rest of Asia Pacific 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2021 14.18.2.1. By Drug 14.18.2.2. By Route of Administration 14.18.2.3. By End User 14.19. GCC Countries 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2021 14.19.2.1. By Drug 14.19.2.2. By Route of Administration 14.19.2.3. By End User 14.20. South Africa 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2021 14.20.2.1. By Drug 14.20.2.2. By Route of Administration 14.20.2.3. By End User 14.21. Israel 14.21.1. Pricing Analysis 14.21.2. Market Share Analysis, 2021 14.21.2.1. By Drug 14.21.2.2. By Route of Administration 14.21.2.3. By End User 14.22. Rest of MEA 14.22.1. Pricing Analysis 14.22.2. Market Share Analysis, 2021 14.22.2.1. By Drug 14.22.2.2. By Route of Administration 14.22.2.3. By End User 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Drug 15.3.3. By Route of Administration 15.3.4. By End User 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Abbott 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Merck & Co., Inc 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. AstraZeneca 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Boehringer Ingelheim International GmbH 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Pfizer Inc. 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. Sanofi 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Teva Pharmaceutical Industries Ltd 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. GlaxoSmithKline Plc 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Johnson & Johnson 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. Roche Holding AG 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Epiglottitis Treatment Market
